Moderna shares advanced 3.7% in pre-open trading after the U.S. Food and Drug Administration approved mFLUSIVA (mRNA-1010), the company's mRNA-based seasonal influenza vaccine for adults aged 50 and older. This marks the first time an mRNA-formulated flu vaccine has received regulatory clearance in the United States.
The FDA awarded full approval for the 50-64 age group on the basis of a Phase 3 trial that enrolled more than 40,000 participants across 11 countries. For adults 65 and older, the agency granted accelerated approval, which is contingent on the completion of a confirmatory postmarketing study.
The path to approval was not straightforward. The FDA issued a refusal-to-file letter in February 2026, prompting Moderna to reorganize its submission by age cohort. That revised approach culminated in a unanimous 9-0 vote by the advisory committee in June 2026. In a company statement, CEO Stéphane Bancel said the approval "demonstrates the continued strength and versatility of our mRNA platform." Moderna said it expects to begin supplying mFLUSIVA to select U.S. retailers within weeks, ahead of the upcoming flu season, and noted the vaccine has been accepted for regulatory review in the European Union, Canada, and Australia.
Market participants treated the development as largely company-specific. While Moderna's pre-market move was positive, broader U.S. markets offered little assistance: the Nasdaq slipped 0.5% while the S&P 500 and Dow Jones industrials were marginally higher. Analysts also maintained a cautious stance. J.P. Morgan was still carrying a Sell rating as recently as August 4, and the consensus among sell-side coverage sits at Hold, with an average price target near $52. That consensus reflects particular concern about the pace of near-term revenue ramp and unresolved insurance coverage tied to an impasse over an Advisory Committee on Immunization Practices recommendation.
For investors and industry observers, the approval represents three concurrent signals: regulatory validation of mRNA in a seasonal vaccine context, an imminent commercial rollout targeted at retail channels, and an internal company endorsement of platform versatility. Those positives pushed shares higher in pre-market trading, but analysts emphasize that issuance of approval does not eliminate uncertainty around uptake, reimbursement, and timing of realized sales.
Contextual note - The FDA's decisions, the size and scope of the Phase 3 program, the advisory committee vote, and Moderna's stated commercial timing are the specific facts underpinning today's market reaction. The remaining open items highlighted by analysts include how quickly the vaccine will convert into meaningful revenue and whether payers will fully cover the product amid an ACIP recommendation impasse.